Alkermes Files Vivitrex NDA; Alcoholism Drug May Have Compliance Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes' Vivitrex is on to track to become the first once-monthly injection for alcohol dependence, providing a potential advantage for patient-compliance monitoring over competitors, the firm says
You may also be interested in...
Alkermes Vivitrex gets priority review
Alkermes' Vivitrex has a Sept. 30 user fee date following FDA's priority review designation for the long-acting naltrexone injection. Vivitrex would be the first once-monthly injection product for treatment of alcoholism; Alkermes has been highlighting the formulation's potential compliance benefit over current alcoholism treatments, most of which are oral (1Pharmaceutical Approvals Monthly April 2005, p. 8). Vivitrex utilizes the company's Medisorb microsphere delivery technology...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product